Screener
Kymera Therapeutics KYMR Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Proceeds from employee stock purchase plan | 1,472 | 1,112 |
| Payments on finance leases | (861) | (659) |
| Net cash provided by financing activities | $33,188 | $245,984 |
| Net decrease in cash, cash equivalents and restricted cash | (232,512) | 215,586 |
| Cash, cash equivalents and restricted cash at beginning of period | 362,811 | 126,050 |
| Cash, cash equivalents and restricted cash at end of period | $130,299 | $341,636 |
| Supplemental disclosure of cash flow activities | ||
| Cash paid for interest | $120 | $154 |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's net change in cash?
- Kymera Therapeutics (KYMR) reported net change in cash of -$19.6M in Q2 2026.
- How has Kymera Therapeutics's net change in cash changed year-over-year?
- Kymera Therapeutics's net change in cash decreased by 108.0% year-over-year, from $245.86M to -$19.6M.
- What is the long-term trend for Kymera Therapeutics's net change in cash?
- Over 2 years (2023 to 2025), Kymera Therapeutics's net change in cash has grown at a 139.6% compound annual growth rate (CAGR), from $41.25M to $236.76M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Kymera Therapeutics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude